Form 4: Edesa Biotech Director Acquires Shares in Private Placement

Carlo Sistilli, a director of Edesa Biotech, purchased 10,416 common shares in a private placement at $1.92 per share.

Summary

• Carlo Sistilli, a director of Edesa Biotech, acquired 10,416 common shares of the company on February 12, 2025.
• The shares were purchased in a private placement at a price of $1.92 per share.
• Following the transaction, Sistilli directly owns 10,416 common shares.
• Sistilli also indirectly owns 522 common shares through York-Cav Enterprises, Inc., in which he has a partial ownership interest.
• A power of attorney has been granted to Pardeep Nijhawan and Stephen Lemieux to execute relevant filings on Sistilli's behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares can be seen as a good sign, but the impact is limited without more context.

Positives

• Director's purchase may signal confidence in the company's prospects.

Industry Context

Director's share purchases are often viewed positively by the market, as they can indicate confidence in the company's future performance. However, the impact depends on the size of the purchase relative to the director's existing holdings and the overall market sentiment.

Stakeholder Impact

• The share purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Edesa Biotech, EDSA, Carlo Sistilli, Director, Share Purchase, Private Placement, Form 4, Beneficial Ownership, Securities Exchange Act, Power of Attorney